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A B S T R A C T
Uterine tumor resembling ovarian sex cord tumor (UTROSCT) is a rare uterine neoplasm of uncertain malignant
potential. We present the case of a 69-year-old woman who underwent hysterectomy for postmenopausal
bleeding and was found to have a myometrial UTROSCT. RNA-sequencing identified a somatic GREB1–NCOA1
fusion, supporting the diagnosis. Next-generation sequencing is increasingly being adopted in diagnostic pa-
thology laboratories. This report highlights the value of RNA-sequencing in identifying rare fusion events to
support pathologic diagnoses.
1. Introduction
Uterine tumor resembling ovarian sex cord tumor (UTROSCT) is a
mesenchymal neoplasm with predominantly sex cord-like differentia-
tion, classified by the World Health Organization as a subset of en-
dometrial stromal and related neoplasms. Fewer than 100 cases of
UTROSCT have been published since the entity was first described
(Schraag et al., 2017), and it is clearly a rare entity, although the true
incidence is difficult to estimate due to its rarity and the historical
absence of a reliable diagnostic marker. UTROSCT usually occurs in
middle-aged women (average age of 50 years) who present with ab-
normal bleeding or pelvic pain (Blake et al., 2014; Clement and Scully,
1976). Hysterectomy with or without bilateral salpingo-oophorectomy
is considered standard treatment for these neoplasms. While typically
considered to be of low malignant potential, a recent series documented
extrauterine metastasis in 8 of 34 patients (Moore and McCluggage,
2017). Although referral bias is likely to be present, the non-negligible
rate of malignant behavior underscores the need for accurate diagnostic
tools for such patients.
Sex cord-like elements are present in a variety of uterine neoplasms.
They can be a focal pattern within endometrioid adenocarcinoma, or
can be mimicked by adenosarcoma, carcinosarcoma, or smooth muscle
tumors. Once these mimickers are excluded, uterine tumors with a bona
fide sex cord-like element have been divided into two groups: group I
tumors, known as endometrial stromal tumors with sex cord-like
elements (ESTSCLE), and group II tumors, comprising classic
UTROSCTs. A recent systematic review showed that subcategorization
is often not reported, but that group I tumors have the greater malig-
nant potential of the two, with disease-free survival at 2 years being
23.8% for group I, but 100% for group II (Blake et al., 2014). Group I
tumors contain focal sex cord-like elements (although > 10% by de-
finition), and these tumors appear to be closely related to low-grade
endometrial stromal sarcomas, sometimes harboring characteristic ge-
netic rearrangements such as JAZF1–SUZ12. Group II tumors appear to
be a separate entity (Blake et al., 2014; Clement and Scully, 1976).
Molecular features of UTROSCT were elusive until RNA sequencing
(RNA-seq) revealed recurrent NCOA1 rearrangements (Dickson et al.,
2019; Goebel et al., 2020), usually partnering with estrogen receptor 1
(ESR1) or growth regulation by estrogen in breast cancer (GREB1).
Here we report a case of a 69-year-old woman with a uterine tumor.
The histopathologic findings were initially equivocal, but RNA-seq
identified a diagnostic GREB1–NCOA1 fusion, supporting classification
as UTROSCT.
2. Case summary
The patient provided consent for publication. A 69-year-old woman
with past medical history significant for breast cancer (stage I ER/PR-
positive, HER-2–negative invasive ductal carcinoma diagnosed in 2010)
presented with postmenopausal bleeding and underwent hysteroscopy
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and D&C in 2016, with removal of a benign endometrial polyp. She had
a recurrent episode of postmenopausal bleeding in February 2019. A
transvaginal ultrasound at that time demonstrated a thickened en-
dometrium at 1.2 cm, as well as an isoechoic 3.9 cm mass within the
myometrium without mass effect on adjacent endometrium. Repeat D&
C in early 2019 revealed no evidence of malignancy. The patient re-
mained symptomatic and desired definitive management. In July 2019,
she underwent robotic-assisted total laparoscopic hysterectomy and
bilateral salpingo-oophorectomy. Operative findings were notable for
normal uterus, tubes and ovaries, vaginal strictures and atrophy, a 2 cm
inclusion cyst on the anterior uterine serosa, and adhesions from as-
cending and descending colon to pelvic sidewalls.
Gross examination of the bivalved uterus showed a
5.2 × 4.1 × 3.2 cm tan-white, well delineated, focally necrotic-ap-
pearing mass. Histology showed a stromal tumor within the myome-
trium, with several histologic components (Fig. 1). One component
consisted of cells with small to medium-sized, round to oval nuclei and
inconspicuous cytoplasm, resembling cells of low-grade endometrial
stromal sarcoma, with a mitotic rate of approximately 1 per 10 high-
power fields. Other more peripheral areas showed similar cells arranged
in cords, tubules and other pseudoglandular configurations, resembling
patterns that can be seen in granulosa cell tumors of the ovary, also
with aggregates of foamy macrophages. Each component was noted to
make up close to 50% of the volume of the tumor. The growth habitus
appeared expansile, but on microscopic examination, the sex cord ele-
ments peripherally infiltrated the myometrium. Margins and serosa
were negative, and lymphovascular invasion was absent. Immunostains
showed tumor cells to be positive for CD10, pancytokeratin (sex cord
elements only), progesterone receptor, calretinin, and vimentin, very
weakly positive for estrogen receptor, and negative for smooth muscle
actin. Inhibin showed multifocal but strong positivity, mainly in the sex
cord-like component.
Several diagnoses were considered. Less likely entities included
carcinosarcoma, adenosarcoma and dedifferentiated endometrioid
adenocarcinoma. More probable entities included low-grade en-
dometrial stromal sarcoma, endometrial stromal tumor with sex cord-
like elements (ESTSCLE) or uterine tumor resembling ovarian sex cord
tumors (UTROSCT). Fluorescence in situ hybridization was negative for
JAZF1, PHF1, or YWHAE rearrangements. RNA-seq (Dickson et al.,
2019) identified a fusion between GREB1 (NCBI Reference Sequence:
NM_014668.3; exon 7 of 33) and NCOA1 (NM_003743.4; exon 13 of 21)
(Fig. 2). The presence of a somatic GREB1-NCOA1 fusion supported a
definitive diagnosis of UTROSCT.
The patient recovered from surgery without complication and was
seen at 2 and 6 weeks postoperatively. No adjuvant therapy was felt to
be indicated. She was without apparent disease at an 8-month post-
operative interval.
3. Discussion
The current World Health Organization (WHO) classification in-
cludes UTROSCT under the category of “endometrial stromal and re-
lated tumors”. However, these tumors do not resemble ovarian sex
cord-stromal tumors nor uterine stromal neoplasms at a molecular
level, despite their morphologic resemblance (Croce et al., 2016; Staats
et al., 2009). Recently, a small number of studies have identified mo-
lecular alterations strongly associated with UTROSCT. A recent study
showed recurrent NCOA2/3 gene fusions in 4 UTROSCTs (ESR1-
NCOA3, n = 2; ESR1-NCOA2, n = 1; GREB1-NCOA2, n = 1) (Dickson
et al., 2019). A subsequent report characterized the features of
4 GREB1-rearranged uterine sarcomas (GREB1-NCOA1, GREB1-
NR4A3, GREB1-SS18, and GREB1-NCOA1), as well as 4 classic
UTROSCT harboring ESR1-NCOA3 (Lee et al., 2019). The GREB1-rear-
ranged sarcomas were said to have limited sex cord differentiation, but
Fig. 1. (A) Spindled elements of tumor. H&E stain, 200x original magnification. (B) Spindled elements at edge of tumor, 200x. (C) Sex cord-like elements of tumor,
200x. (D) Juxtaposition of spindled and sex cord-like areas, 200x.
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our case with NCOA1-GREB1 showed reasonably strong sex cord fea-
tures.
In response to those initial studies, Goebel et al. sought to further
describe the molecular characteristics of this rare tumor using a larger
cohort of 26 UTROSCT cases. A majority of cases showed
NCOA1, NCOA2, or NCOA3 gene fusions (18/22). The most commonly
identified fusion partners were ESR1 or GREB1 (17/22). Further, a
subset of the UTROSCTs were analyzed for alterations characteristic of
low-grade stromal neoplasms (JAZF1-SUZ12 translocations
and PHF1 rearrangements), all of which were negative (Goebel et al.,
2020).
ESR1 (estrogen receptor 1) is a ligand-dependent transcription
factor and GREB1 (growth regulation by estrogen in breast cancer) is
expressed in all ESR1-expressing tissues, and is a mediator of estrogen
activity (Dickson et al., 2019). NCOA1-3 genes encode a family of nu-
clear receptor co-activators (p160/Src family) that, when bound to
nuclear receptors, stimulate transcription in a hormone-dependent
manner. Their role in steroid hormone-dependent uterine function and
has been described (Szwarc et al., 2014). It has been surmised that these
fusions cause uterine disease because ESR1 and GREB1 are highly ex-
pressed in uterine tissue. The putative fusion oncoproteins retain the
active promoter region of ESR1/GREB1 fused to the nuclear receptor
co-activator domain of NCOA1–3. This would result in dysregulated
expression of the nuclear receptor co-activator domain of NCOA1–3
(Dickson et al., 2019). Functional studies supporting this hypothesis
have not been reported.
Making a distinction between UTROSCT and ESTSCLE may be dif-
ficult on morphologic grounds. Given the difference in malignant po-
tential of these two subtypes, however, the distinction is clinically re-
levant. While optimal postoperative surveillance methods are not
standardized at this time, definite diagnosis allows for more appro-
priate monitoring. With the more aggressive behavior of ESTSCLE, a
period of postoperative imaging may be warranted, whereas clinical
surveillance alone is likely appropriate for type II (UTROSCT) tumors.
In conclusion, the present case showed a somatic GREB1-NCOA1
fusion, supporting the diagnosis of UTROSCT. This newly recognized
molecular event can aid in distinguishing these rare, apparently in-
dolent tumors from more aggressive morphologic mimics.
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